Personalized vaccine cuts melanoma risk by 42% in trial
By The BriefBrief
Researchers say a trial found a personalized cancer vaccine reduced the risk of melanoma recurrence or death by 42%. They described the findings as a possible step toward treatments designed to stimulate the immune system against cancer cells remaining after surgery.
WHO:Researchers
WHAT:Researchers reported trial findings that a personalized cancer vaccine reduced the risk of melanoma recurrence or death by 42%.
WHEN:Reported Oct 23, 2026 at 12:01 PM ET
WHERE:Location not specified
WHY:The vaccine is designed to stimulate the immune system against cancer cells remaining after surgery.
Reporting from 3 identified publishers across this event arc.
